Tag: Bisantrene

Phase 1b dose escalation stage of the Phase 1b/2 Zantrene study in AML has completed using a 4-day treatment of Zantrene in combination with fludarabine and clofarabine Encouraging clinical responses were observed in this very heavily pre-treated AML patient population…

6 April 2022 – Race Oncology Limited (“Race”) is pleased to announce it has receivedhuman ethics approval for its open label clinical trial of Zantrene® (bisantrenedihydrochloride) in patients with extramedullary Acute Myeloid Leukaemia (AML) or highrisk Myelodysplastic Syndrome (MDS). Before…

25 January 2022 – Race Oncology Limited (“Race”) is pleased is pleased to share details of a recent independent scientific publication in the journal Cells, confirming Zantrene® (bisantrene dihydrochloride) is a highly effective inhibitor of the Fat Mass and Obesity…

Race Oncology CEO/MD Phil Lynch speaks to Matt Birney of the Bulls n’ Bears Report about Race’s latest results and outlook.

10 December 2021 – Race Oncology Limited (“Race”) is pleased to announce it has extended and expanded its collaborative cardio-protective research program for Zantrene® (bisantrene dihydrochloride) with eminent cardiotoxicity researchers, Associate Professors Aaron Sverdlov and Doan Ngo, at The University…

08 December 2021 – Race Oncology Limited (“Race”) is pleased to share additional interim results from the Zantrene® (bisantrene dihydrochloride) preclinical heart safety research program led by eminent cardiotoxicity researchers, Associate Professors Aaron Sverdlov and Doan Ngo, in collaboration with…